Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus 19070-2 + lactobacillus reuteri DSM 12246
- Development stage
- Unknown
- Lead developer
- DSM-Firmenich
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus 19070-2 + Lactobacillus reuteri DSM 12246 is a probiotic combination developed by DSM (now DSM-Firmenich) and marketed under the brand name FloraActive™. The product consists of two specific live bacterial strains that colonize the gastrointestinal tract, where they exert antimicrobial activity against pathogenic bacteria and stabilize the intestinal mucosal barrier. Clinical studies have demonstrated its efficacy in reducing the duration of acute diarrhea in children, decreasing crying and fussing time in infants with colic, and alleviating gastrointestinal symptoms and skin severity in children with atopic dermatitis. The combination has received FDA New Dietary Ingredient (NDI) no-objection status and is commercially available globally as a dietary supplement.
- Other names
- Lactobacillus rhamnosus 19070-2 + Lactobacillus reuteri DSM 12246L. rhamnosus 19070-2 + L. reuteri DSM 1224612246-CU
Beyond the preview
Go deeper on lactobacillus rhamnosus 19070-2 + lactobacillus reuteri DSM 12246.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus 19070-2 + lactobacillus reuteri DSM 12246.